AGA Family of Websites:

AGA announces new partnership with Target RWE to gather real world data on eosinophilic esophagitis (EoE)

Target RWE to implement AGA’s EoE severity index tool in new research study.

Bethesda, MD (April 15, 2024) – The American Gastroenterological Association (AGA) and Target RWE have partnered to significantly expand real-world data available for serious, and often chronic, gastroenterological diseases. This partnership will also allow Target RWE to incorporate AGA’s eosinophilic esophagitis (EoE) severity index tool, I-SEE, into the TARGET-GASTRO registry.  

AGA led the international team of more than 30 multidisciplinary experts that developed the Index of Severity for EoE (I-SEE) in 2022. I-SEE is the first-ever severity index for eosinophilic esophagitis, which provides a simple system for physicians to assess and track EoE activity at the point-of-care using a mobile app. The I-SEE tool was initially validated in retrospective analyses in both adults and children 

“As the number of children and adults with EoE increases worldwide, a simple system to assess and track disease activity in a meaningful way in a clinical setting is needed,” said Evan S. Dellon, MD, MPH, professor of medicine in the division of gastroenterology and hepatology and director of the center for esophageal diseases and swallowing at the University of North Carolina School of Medicine, Chapel Hill. “The I-SEE tool is an important part of evolving and improving EoE care for all.” 

TARGET-GASTRO is a longitudinal registry of patients with GI-related diseases, including EoE, inflammatory bowel disease, Clostridioides difficile (C. diff) infection (CDI) and celiac disease (CeD), with an average of 42 months of patient follow-up. The registry captures the natural history, management, and health outcomes of patients in the real world to allow AGA to compare treatment options and patient journeys to advance the research of gastroenterological diseases. 

“Gastroenterology diseases are at an inflection point where there is another wave of innovation on the horizon. There is a high unmet need for new therapies, but solutions are coming. We are thrilled to bring our advanced analytics and well-established TARGET-GASTRO community to AGA to help inform how those innovations can be optimally implemented in practice,” said Michael W. Fried, MD, FAASLD, co-founder and chief medical officer of Target RWE. 

As part of the new collaboration, AGA will have access to Target RWE’s robust data platform which abstracts and curates fit-for-purpose real-world evidence from electronic health records. The new partnership offers AGA researchers an environment in which research can be performed with minimal cost impact to their organizations, and have access to Target RWE’s clinical, statistical, and epidemiological personnel. 

TARGET-GASTRO is still recruiting sites, please contact [email protected] if you are interested in enrolling your practice. 


Read more and access the I-SEE tool:  

Download I-SEE app for Apple iOS:  

Download I-SEE app for Android: 

Visit AGA’s EoE Patient Resource Center:  

AGA Media Contact: Mara Shapiro, Communications and Media Relations Manager, [email protected], 301-329-5709  

Target RWE Media Contact: Kayla Slake, Senior Manager, Marketing, [email protected], 984.234.0268 ext 205 

About the AGA Institute    

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization.    

AGA is on Instagram.    
Like AGA on Facebook.   
Follow us on X @AmerGastroAssn  
Check out our videos on YouTube.     
Join AGA on LinkedIn. 

About Target RWE 
As the industry’s best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives. 

Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. 

Follow us on X (@TargetRWE) and LinkedIn to keep up with the latest news! 

This program was supported by Genzyme Corporation and Bristol Myers Squibb.

AGA clinical guidance

Find the latest evidence-based recommendations for treating your patients.